Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31068457)

  • 1. Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen Receptor in Prostate Cancer.
    Gonthier K; Poluri RTK; Weidmann C; Tadros M; Audet-Walsh É
    Mol Cancer Res; 2019 Aug; 17(8):1699-1709. PubMed ID: 31068457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
    Gonthier K; Weidmann C; Berthiaume L; Jobin C; Lacouture A; Lafront C; Harvey M; Neveu B; Loehr J; Bergeron A; Fradet Y; Lacombe L; Riopel J; Latulippe É; Atallah C; Shum M; Lambert JP; Pouliot F; Pelletier M; Audet-Walsh É
    Mol Oncol; 2023 Oct; 17(10):2109-2125. PubMed ID: 37086156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
    Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
    Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway.
    Zhang L; Qi M; Feng T; Hu J; Wang L; Li X; Gao W; Liu H; Jiao M; Wu Z; Bai X; Bie Y; Liu L; Han B
    Neoplasia; 2018 Feb; 20(2):207-217. PubMed ID: 29331887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
    Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.
    Whitworth H; Bhadel S; Ivey M; Conaway M; Spencer A; Hernan R; Holemon H; Gioeli D
    PLoS One; 2012; 7(6):e38950. PubMed ID: 22761715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.
    Cheng Y; Wang D; Jiang J; Huang W; Li D; Luo J; Gu W; Mo W; Wang C; Li Y; Gu S; Xu Y
    Prostate; 2020 May; 80(8):640-652. PubMed ID: 32282098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling.
    Xu H; Sun Y; You B; Huang CP; Ye D; Chang C
    Cancer Lett; 2020 Mar; 472():151-164. PubMed ID: 31846689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.
    Tan PY; Chang CW; Chng KR; Wansa KD; Sung WK; Cheung E
    Mol Cell Biol; 2012 Jan; 32(2):399-414. PubMed ID: 22083957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity.
    Link KA; Balasubramaniam S; Sharma A; Comstock CE; Godoy-Tundidor S; Powers N; Cao KH; Haelens A; Claessens F; Revelo MP; Knudsen KE
    Cancer Res; 2008 Jun; 68(12):4551-8. PubMed ID: 18559499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
    Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
    Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.